Condition (MeSH)
Wet Macular Degeneration
ClinicalTrials.gov lists 93 trials for Wet Macular Degeneration or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 14.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
93 of the 93 trials are tagged with Wet Macular Degeneration itself; the rest are tagged with a narrower condition beneath it.
When did Wet Macular Degeneration trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 11
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 7 |
| 2021 | 10 |
| 2020 | 9 |
| 2019 | 11 |
| 2018 | 5 |
| 2017 | 5 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 11 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 66 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Wet Macular Degeneration trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 6 |
| Phase 2 | 16 |
| Phase 2/3 | 7 |
| Phase 3 | 19 |
| Phase 4 | 16 |
| Not applicable | 8 |
| Observational | 17 |
How many Wet Macular Degeneration trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 8 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 9 |
| Completed | 58 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Wet Macular Degeneration trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 14 |
| Bayer | 8 |
| Outlook Therapeutics, Inc. | 5 |
| AbbVie | 4 |
| 4D Molecular Therapeutics | 3 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Wet Macular Degeneration? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Brolucizumab | 6 |
| ADVM-022 | 3 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 2.0 aflibercept | 23 |
| ranibizumab PRN | 21 |
| Bevacizumab 1 | 6 |
| Sham Procedure | 3 |
| 4D-150 IVT | 3 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Wet Macular Degeneration trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 57 | 11 |
| Atrial fibrillation | 34 | 7 |
| COVID-19 pneumonia | 34 | 9 |
| COVID-19 | 32 | 8 |
| Neovascular age-related macular degeneration | 25 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Wet Macular Degeneration? (240)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial. | Ophthalmology | 2026 | Yes |
| Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration. | BMJ open ophthalmology | 2026 | Yes |
| Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial Development. | Ophthalmology. Retina | 2025 | Yes |
| Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration. | Ophthalmology. Retina | 2025 | Yes |
| Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER. | Ophthalmology. Retina | 2025 | Yes |
Showing 5 of 240 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.